Compare Goodyear Tire & Rubber Co (GT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs ResMed Inc. — how do they compare? Goodyear Tire & Rubber Co trades at $4.68 (market cap $1.37B), while ResMed Inc. trades at $230.06 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 23.3× Goodyear Tire & Rubber Co's market cap, and ResMed Inc. pays a 1.16% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and ResMed Inc. for 51 Days on average.
| GT | RMD | |
|---|---|---|
Market Cap | $1.37B | $31.89B |
Volume | 9,470,773 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $277.88 |
52-Week Low | $4.66 | $182.82 |
Typical Hold Time | 57 Days | 51 Days |
Enterprise Value | $8.72B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear (GT) trades at $4.68, down 0.21% on the day, with a bearish technical signal and weak profitability metrics including a negative net income margin and ROE. Recent earnings show mixed results, with a Q2 2026 loss of $0.61 per share beating expectations but revenue declining. The company's restructuring efforts focus on premium tire segments and cost management, while cash flow trends show modest improvement with a net cash flow of $46 million in 2025.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include volume pressure, competitive threats, and execution of the turnaround plan. Investment opportunity hinges on successful margin expansion and debt reduction, though near-term volatility is likely amid macroeconomic headwinds.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
